H2-DMα−/− Mice Show the Importance of Major Histocompatibility Complex–Bound Peptide in Cardiac Allograft Rejection by Felix, Nathan J. et al.
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2000/07/31/10 $5.00
Volume 192, Number 1, July 3, 2000 31–40
http://www.jem.org/cgi/current/full/192/1/31
 
31
 
H2-DM
 
a
 
2
 
/
 
2
 
 Mice Show the Importance of
Major Histocompatibility Complex–bound 
Peptide in Cardiac Allograft Rejection
 
By Nathan J. Felix,
 
* 
 
W. June Brickey,
 
*
 
  
 
Robert Grifﬁths,
 
‡
 
Jinghua Zhang,
 
* 
 
Luc Van Kaer,
 
§ 
 
Thomas Coffman,
 
‡
 
and Jenny P.-Y. Ting
 
*
 
From the 
 
*
 
University of North Carolina Lineberger Comprehensive Cancer Center, Department of 
Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North 
 
Carolina 27599; the 
 
‡
 
Department of Medicine and the Transplantation Laboratory, Durham Veterans 
Administration and Duke University Medical Center, Durham, North Carolina 27705; and the 
 
§
 
Howard Hughes Medical Institute, Department of Microbiology and Immunology, Vanderbilt 
University School of Medicine, Nashville, Tennessee 37232
 
Abstract
 
The role played by antigenic peptides bound to major histocompatibility complex (MHC)
 
molecules is evaluated with H2-DM
 
a
 
2
 
/
 
2
 
 mice. These mice have predominantly class II–asso-
ciated invariant chain peptide (CLIP)-, not antigenic peptide–bound, MHC class II. H2-
DM
 
a
 
2
 
/
 
2
 
 donor heart grafts survived three times longer than wild-type grafts and slightly
longer than I-A
 
b
 
b
 
2
 
/
 
2
 
 grafts. Proliferative T cell response was absent, and cytolytic response was
reduced against the H2-DM
 
a
 
2
 
/
 
2
 
 grafts in vivo. Residual cytolytic T cell and antibody re-
sponses against intact MHC class I lead to eventual rejection. Removal of both H2-DM
 
a
 
 and
 
b
 
2-microglobulin (
 
b
 
2m) in cardiac grafts lead to greater (8–10 times) graft survival, whereas
removal of 
 
b
 
2m alone did not have any effect. These results demonstrate the significance of
peptide rather than just allogeneic MHC, in eliciting graft rejection.
Key words: major histocompatibility complex class II • H2-DM • class II–associated antigenic 
peptide • alloreactivity • transplantation
 
Introduction
 
Allogeneic MHC represents a major barrier to transplant
acceptance (1, 2). Donor MHC antigens can trigger rejec-
tion through two pathways: (a) by interacting directly with
recipient T cells, or (b) indirectly, as donor MHC-derived
peptides expressed on recipient MHC molecules (3). Al-
though both MHC class I and class II molecules are targets
of allospecific responses, class II antigens play the predomi-
nant role in cardiac graft rejection, as elimination of class II
expression significantly enhances cardiac graft survival,
whereas eliminating class I has very little effect (4–7).
T cells recognize nominal antigen during an immune re-
sponse as peptide complexed to self-MHC. However, it is
unclear how recipient T cells interact with allogeneic do-
nor MHC. The three main theories developed to explain
alloreactivity differ in the posited role of the MHC-bound
peptide (8–12). The first is the peptide-specific (or molecu-
lar mimicry) model, in which alloantigen is thought to
mimic the structure of antigen complexed to self-MHC.
Crystallographic analysis of alloreactive T cell clones has in-
dicated that some molecular mimicry occurs. However, the
TCR–MHC interactions in the self-MHC–X complex are
substantially different from the interactions in the allo-
MHC–Y complex (13–15). For example, there was an in-
crease in the number of direct contacts between the TCR
and polymorphic regions of the allo-MHC. This has the
effect of decreasing TCR specificity for peptide. Alloreac-
tive clones have, in general, been found to respond to a
range of degenerate peptides (13, 15–20). These observa-
tions are consistent with the second model, which is pep-
tide-dependent allorecognition. Peptide-dependent allore-
active T cells respond to peptide-induced conformational
changes in the MHC, but do not interact specifically with
the peptide. According to the third model, alloreactive T
cells contact polymorphic regions of allo-MHC in a pep-
tide-independent fashion (8). In this case, polymorphisms
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in the MHC molecule itself are recognized by T cells, elic-
iting a strong alloresponse even in the absence of bound
peptide. This possibility has been formally demonstrated in
some instances of class I allorecognition (21–23), and in
one case, peptide-independent CTLs were sufficient to re-
ject allogeneic skin grafts (23). However, peptide-indepen-
dent recognition has yet to be detected during an MHC
class II–directed response.
Most of the evidence addressing the role of peptide in al-
loimmune responses could only be performed in simple in
vitro systems using T cell clones. The recent development
of mouse models expressing a single peptide–MHC class II
complex has provided an experimental model to test this
issue in vivo using vascularized organ grafts. One such
mouse was generated by the inactivation of the H2-DM
 
a
 
gene, also called H2-Ma (24–26). H2-DM dimers are
found in the antigen processing and presenting compart-
ments of the class II pathway (27). There, it catalyzes the
removal of the invariant chain–derived class II–associated
invariant chain peptide (CLIP)
 
1
 
 from newly formed class II
molecules (28–30). H2-DM further enhances peptide load-
ing by facilitating the loading of foreign peptides onto
MHC class II molecules (31–33). However, the depen-
dence on H2-DM for peptide exchange varies between
peptides and class II alleles. For example, I-A
 
k
 
 molecules
are perhaps the least dependent upon H2-DM for peptide
loading, and can spontaneously disassociate from CLIP and
bind antigenic peptide. I-A
 
b
 
 molecules, on the other hand,
are extremely dependent upon H2-DM expression for dis-
association from CLIP and peptide loading (34–37).
H2-DM
 
a
 
2
 
/
 
2
 
 mice lack functional H2-DM dimers. As a
result, most class II molecules on the surface of H2-DM
 
a
 
2
 
/
 
2
 
cells are bound to the invariant chain–derived CLIP pep-
tide (24–26). Despite restricting the peptide repertoire to a
predominant peptide, CLIP, the level of class II expression
is normal on cells isolated from these mice. However, it is
clear that some non-CLIP peptides are bound with class II
on H2-DM
 
a
 
2
 
/
 
2
 
 mice, and that some of the CD4
 
1
 
 T cells
in H2-DM
 
a
 
2
 
/
 
2
 
 mice are selected by these non-CLIP pep-
tides (38).
In this report, H2-DM
 
a
 
2
 
/
 
2
 
 mice were used to examine
the role of peptide in allorecognition. H2-DM
 
a
 
2
 
/
 
2
 
 donor
hearts grafted into fully allogeneic recipients display a re-
duced rate of rejection comparable to that observed for
class II null donor grafts. The data presented suggest that
targeting the peptides presented by allo-MHC may be an
effective way of preventing graft rejection. This is the first
report that takes advantage of these mice to demonstrate
the significant role of peptide in an allograft response.
 
Materials and Methods
 
Animals.
 
(Balb/c 
 
3
 
 DBA/2)F1 (also known as CBYD2F1/J,
H2
 
d
 
, hereafter referred to as CBY), C57BL/6 (B6, H2
 
b
 
), and 
 
b
 
2-
 
microglobulin (
 
b
 
2m)
 
2
 
/
 
2
 
 (H2
 
b
 
) mice on the B6 background were
purchased from The Jackson Laboratory. H2-DM
 
a
 
2
 
/
 
2
 
 mice
were backcrossed onto the B6 (H2
 
b
 
) background for nine gener-
ations, and I-A
 
b
 
b
 
2
 
/
 
2
 
 mice have been backcrossed onto the B6
background for 
 
.
 
6 generations. B6-backcrossed H2-DM
 
a
 
2
 
/
 
2
 
mice were also bred with 
 
b
 
2m
 
2
 
/
 
2
 
 mice and further intercrossed
to produce double knockout (DKO) mice lacking expression of
H2-DM
 
a
 
 and 
 
b
 
2m (H2-DM
 
a
 
2
 
/
 
2
 
 
 
3
 
 
 
b
 
2m
 
2
 
/
 
2
 
). H2-DM
 
a
 
2
 
/
 
2
 
,
I-A
 
b
 
b
 
2
 
/
 
2
 
, and DKO mice were bred and maintained at the Uni-
versity of North Carolina at Chapel Hill. All mice were housed
and maintained under specific pathogen-free conditions.
 
Mouse Heart Transplantation.
 
Vascularized heterotopic car-
diac grafts were performed as described previously (39). In brief,
donor and recipient animals were anesthetized with isoflurane,
and the donor heart was harvested. The donor aorta and pulmo-
nary artery were anastamosed to the recipient abdominal aorta
and vena cava, respectively. The graft was monitored daily for the
presence of palpable contractions, and was considered rejected
when contractions ceased.
Control allografts (
 
n
 
 
 
5 
 
14) consisted of donor hearts from B6
mice (H2
 
b
 
) transplanted into fully allogeneic CBY animals (H2
 
d
 
).
For control isografts (
 
n
 
 
 
5 
 
8), hearts from CBY mice were trans-
planted into CBY recipients. The experimental groups consisted
of either H2-DM
 
a
 
2
 
/
 
2
 
 (
 
n
 
 
 
5 
 
8), I-A
 
b
 
b
 
2
 
/
 
2
 
 (
 
n
 
 
 
5 
 
12), 
 
b
 
2m
 
2
 
/
 
2
 
 (
 
n
 
 
 
5
 
7), or DKO mice (H2-DM
 
a
 
2
 
/
 
2
 
 
 
3 b
 
2m
 
2
 
/
 
2
 
,
 
 n 
 
5 
 
6) donor hearts
(H2
 
b
 
) transplanted into fully allogeneic CBY recipients (H2
 
d
 
).
Statistical significance was assessed using the Mann-Whitney U
Test.
 
In Vitro T Cell Responses.
 
MLRs were performed by incubat-
ing 2.5 
 
3
 
 10
 
5
 
 T cell–enriched responders with titrated numbers
of irradiated (2,500 rads) spleen cell stimulators in 96-well plates
for 4–6 d at 37
 
8
 
C and 5% CO
 
2
 
. Cells were cultured in complete
DMEM containing 10% FCS, 25 mM Hepes, 2 mM 
 
l
 
-glutamine,
1% nonessential amino acids, 50 
 
m
 
M 2-ME, 100 U/ml penicillin,
and 100 
 
m
 
g/ml streptomycin sulfate. Cultures were pulsed with 1
 
m
 
Ci [
 
3
 
H]thymidine per well 12–18 h before harvest.
Cell-mediated alloimmunity was assessed by the DNA frag-
mentation assay (JAM test) (40). Heart graft recipient spleen cells
were harvested and cocultured with equal numbers of irradiated
(2,500 rads) allogeneic spleen cells from the same mouse strain as
the original donor heart graft in complete DMEM for 6 d. Effec-
tors were then recovered, washed, and incubated with labeled
targets (10,000 per well) at the indicated E/T ratios for 3–4 h be-
fore being harvested and counted. Targets consisted of B6 and
CBY Con A blasts that were labeled with [
 
3
 
H]thymidine (5 
 
m
 
Ci/
ml) for 3–6 h before use. Percent cytotoxicity was determined
according to the formula [(S
 
2
 
E)/S] 3 100, where E is the aver-
age experimental release of triplicate samples and S is the average
spontaneous release of numerous samples.
Cytokine RNA Analysis. At the time of harvest, a portion of
the recipient animals’ hearts, both native and donor, were snap
frozen in LN2. At a later date, Trizol (GIBCO BRL) was used to
extract total RNA from these tissues. Cytokine RNA levels were
determined by RNase protection analysis following the kit man-
ufacturer’s protocol (RNA probe sets mCK-1 and mCK-3b; BD
PharMingen). Approximately 2 mg total RNA was analyzed per
sample. Protected bands were quantitated by phosphoimaging
(Molecular Dynamics), and were normalized to glyceraldehyde
3-phosphate dehydrogenase (GAPDH).
Immunohistochemistry. Donor hearts were harvested 7 d after
grafting. A portion of the grafted heart was frozen in OCT em-
bedding compound (Tissue-Tek) before sectioning (5 mm) and
staining. Acetone-fixed frozen sections were stained overnight at
1Abbreviations used in this paper: b2m, b2-microglobulin; B6, C57BL/6;
CBY, CBYD2F1/J; CLIP, class II–associated invariant chain peptide;
DKO, double knockout.33 Felix et al.
48C with biotinylated antibody against either CD4, CD8, or
CD11b (Mac-1; BD PharMingen). The sections were then
washed in 13 PBS and developed using the ABC and DAB-Ni
reagent kits according to the manufacturers’ instructions (Vector
Laboratories).
Allospecific Antibody Quantitation and Flow Cytometry. Allospe-
cific antibodies were detected by indirect, two-color flow cytom-
etry. At the time of graft failure, serum samples were collected and
frozen for later analysis. On the day of the assay, splenic lympho-
cytes were collected from CBY mice, class II–deficient (I-Ab
b2/2)
mice, and mice lacking expression of both class II and class I (I-
Ab
b2/2 3 b2m2/2). CBY splenic lymphocytes served as a nega-
tive control, and MHC-negative (I-Ab
b2/2 3 b2m2/2) lympho-
cytes were used to demonstrate the MHC specificity of recipient
serum alloantibodies. I-Ab
b2/2 spleen cells, which lack surface
MHC class II expression, were used to detect alloantibodies di-
rected against donor MHC class I. Splenic lymphocytes were re-
suspended in HBSS containing 3% FCS. Red blood cells were
lysed by incubation with 155 mM ammonium chloride for 5 min
at 48C. Cell surface staining was performed by preincubating 106
cells with FcBlock (BD PharMingen) for 30 min at 48C. Diluted
recipient serum or normal CBY mouse serum, as a negative con-
trol, was then added to the cells and further incubated for 1 h at
48C. The cells were then washed three times and incubated with
both a FITC-labeled goat anti–mouse Ig antibody (BD PharMin-
gen), to detect Ig bound to the cell surface, and a PE-labeled rat
anti–mouse B220 antibody (BD PharMingen), to identify B cells.
Lymphocytes were identified according to their forward and side
scatter profiles, and a total of 10,000 events was collected using a
Becton Dickinson FACScan™. B2201 cells were selected and an-
alyzed for alloantibody staining using the Cicero software pro-
gram (Cytomation). Alloantibody staining is presented as the
change in mean channel fluorescence (DMCF 5 MCF sample di-
lution 2 MCF normal mouse serum control).
For surface MHC class II analysis, cell suspensions were pre-
pared and cell staining was performed essentially as described
above for alloantibody quantitation. The anti–I-Ab antibodies
M5/114.15.2, AF6-120.1, KH74, and their corresponding iso-
type controls were purchased from BD PharMingen. The anti–
class II antibody NIMR-4 and its isotype control were purchased
from Southern Biotechnology Associates, Inc. Cells were ana-
lyzed using a FACScan™ flow cytometer and CELLQuest™
software (Becton Dickinson).
Results
Naive Allogeneic T Cells Do Not Respond to H2-DMa2/2
APCs In Vitro. Alloreactive T cells have been suggested
to represent 1–10% of the total T cell population (11). This
observation is supported by the strong in vitro proliferation
typically associated with an MLR. Two previous reports
found H2-DMa2/2 spleen cells are defective in stimulating
the proliferation of allogeneic T cells (24, 25), whereas a
third group reported that H2-DMa2/2 APCs induce allo-
geneic T cell proliferation (26). Each of these groups used
H2-DMa2/2 mice on a mixed genetic background. For
this study, all of the H2-DMa2/2 mice have been back-
crossed to B6 mice for nine generations. This is particularly
critical for these experiments because (a) background genes
greatly influence the outcome of transplant acceptance
and/or rejection; (b) other transgenic mice used in this re-
port are backcrossed onto the same genetic background;
and (c) H2-DM has the most dramatic role in loading pep-
tides onto class II from H2b mice (34–37). To evaluate the
ability of these H2-DMa2/2 mice to stimulate allogeneic T
cells, a one-way MLR was performed. Allogeneic T cells
proliferate minimally in response to B6-backcrossed H2-
DMa2/2 APCs, even though they responded well to B6
APCs (Fig. 1 A). As expected, allogeneic T cells also failed
to react against H2-DMa2/2 cells from the mixed B6 3
129 background (Fig. 1 B). Thus, allogeneic CLIP–I-Ab
complexes do not trigger significant allospecific prolifera-
tion in vitro.
The inability to respond to H2-DMa2/2 cells is not due
to a decrease in the amount of surface MHC class II ex-
pressed by our inbred animals. The MHC class II staining
profile of spleen cells from inbred H2-DMa2/2 animals is
identical to that displayed by the mixed-background ani-
mals. Both mixed-background and inbred H2-DMa2/2
mice express as much surface MHC class II as wild-type B6
animals when detected with the anti–class II antibodies
Figure 1. Naive CBY T cells do not respond to H2-DMa2/2 APCs.
Splenocytes from H2-DMa2/2 and B6 mice were used to stimulate T cells
isolated from naive CBY mice that were not implanted with allografts.
Mixed lymphocyte reactions were cultured for 5–6 d. Cell proliferation was
determined by measuring uptake of [3H]thymidine added 12–18 h before
harvest. Splenocytes from (A) B6-backcrossed H2-DMa2/2 mice and (B)
mixed-background B6 3 129 H2-DMa2/2 mice are inefficient activators
of allogeneic T cell proliferation. (C) The reduced proliferative response
is not due to a decrease in surface MHC class II expression. As expected,
both mixed-background and inbred H2-DMa2/2 mice express a level of
MHC class II equivalent to that of wild-type B6 animals, as detected by
three anti–MHC class II antibodies. KH74 detects MHC class II–CLIP
complexes poorly, and as expected, produced a smaller signal when used to
label H2-DMa2/2 cells.34 Peptide Plays a Crucial Role in Allograft Recognition
AF6-120.1, NIMR-4, and M5/114 (Fig. 1 C). The anti–
I-Ab antibody KH74 stains H2-DMa2/2 cells poorly, con-
sistent with this antibody’s previously suggested low affinity
for CLIP–I-Ab complexes (24).
Elimination of H2-DMa Inhibits Allospecific Recognition In
Vivo. Allogeneic class II is the major contributor to the
rejection of vascularized cardiac grafts (4–7). In these pre-
vious studies, the use of I-Ab
b2/2 mice as donors signifi-
cantly prolonged the survival of the graft, and in some do-
nor/recipient strain combinations led to indefinite graft
survival. However, the role of the MHC-bound peptide
has not been evaluated in vivo. H2-DMa2/2 mice allow
this question to be addressed because, although their level
of class II expression is normal, virtually all the class II mol-
ecules expressed by these animals are bound to the CLIP
peptide.
As donors, H2-DMa2/2 heart grafts survived for a sig-
nificantly prolonged time compared with B6 controls
when transplanted into allogeneic recipient mice. The me-
dian survival of H2-DMa2/2 grafts is 24 d, with an average
survival of .40 d (Fig. 2). The median and average survival
time of control B6 grafts is 9 d, which is similar to our pre-
vious experience. The median survival of H2-DMa2/2
grafts was slightly greater than that observed for allogeneic
class II negative control I-Ab
b2/2 grafts, with a median sur-
vival of 20 d. Therefore, targeting peptide presentation ef-
fectively eliminated recognition of allogeneic class II.
Even more surprising, three of the H2-DMa2/2 grafts
survived for a greatly prolonged period of time, with two
grafts surviving for .100 d, and one graft surviving for 48 d
(Fig. 2). Although indefinite survival of I-Ab
b2/2 cardiac
grafts has been seen with some donor/recipient strain com-
binations, the donor/recipient strains used in this study re-
sult in the rejection of I-Ab
b2/2 cardiac grafts, with a me-
dian survival of 20 d, and no I-Ab
b2/2 grafts survived
beyond 30 d. The prolonged survival of some H2-DMa2/2
grafts suggests that the elimination of peptide presentation
may be even more effective at delaying or preventing graft
rejection than the elimination of donor class II expression.
In Vivo Stimulation with H2-DMa2/2 Grafts Failed to Ex-
pand Alloreactive T Cells. One possible explanation for the
delayed rejection of H2-DMa2/2 grafts is that the precur-
sor frequency of CLIP–I-Ab–specific T cells is low in the
recipients, and it simply takes longer for these cells to ex-
pand and efficiently mediate graft rejection. If this were the
case, allogeneic T cells that recognize H2-DMa2/2 cells
should be expanded after in vivo immunization with the
cardiac allograft. To determine if donor-specific T cells had
developed in recipients of H2-DMa2/2 grafts, an MLR
analysis of spleen cells was performed from animals that had
received cardiac allografts. The spleens from graft recipients
were harvested 7 d after transplant, enriched for T cells,
and stimulated with irradiated allogeneic cells. Primed allo-
geneic T cells from recipients of H2-DMa2/2 hearts re-
mained refractory to stimulation by H2-DMa2/2 APCs,
whereas these same cells responded well to B6 stimulators
(Fig. 3 A). The same pattern was observed for T cells from
naive animals (Fig. 3 B). Although H2-DMa2/2 cells ex-
Figure 2. (A) Cardiac grafts from inbred H2-DMa2/2 mice, as well as
inbred I-Ab
b2/2 mice, exhibit enhanced survival in our allogeneic hosts.
Cardiac grafts from the indicated donors (H2b) were grafted into the ab-
domen of CBY (H2d) recipient mice. Graft survival was monitored daily
by palpation of the abdomen. Each point represents an individual, and the
line in each group represents the median survival. The median survival of
cardiac grafts from B6 wild-type allogeneic controls was 9 d (n 5 14),
from H2-DMa2/2 mice, 24 d (n 5 8, P , 0.0007), and from I-Ab
b2/2
mice, 20 d (n 5 12, P , 0.0006). Control isografts were not rejected
(n 5 8, data not shown). Statistical significance was determined using the
Mann-Whitney U test compared with B6 control donors.
Figure 3. Primed CBY lymphocytes,
which reject H2-DMa2/2 grafts, do not re-
spond to H2-DMa2/2 stimulator cells in a
secondary MLR. Total splenocytes from
H2-DMa2/2 and B6 mice were isolated, ir-
radiated, and combined with spleen cells
isolated from recipients of H2-DMa2/2
grafts. (A) These cells responded to irradi-
ated stimulator cells from B6 controls (j),
but not H2-DMa2/2 animals (h). Data are
means 6 SD of four animals. (B) The same
pattern is observed from naive animals.
Mixed lymphocyte reactions were cultured
for 5–6 d. Cell proliferation was determined
by measuring uptake of [3H]thymidine
added 12–18 h before harvest.35 Felix et al.
press normal levels of class II, the recipients of H2-DMa2/2
hearts failed to develop significant CD41 T cell reactivity
to CLIP– I-Ab complexes.
T Cells from H2-DMa2/2 Graft Recipients Generate Type 1
and Type 2 Cytokine RNA. To explore the underlying
mechanism for the enhanced survival of H2-DMa2/2
grafts, cytokine RNA profile was analyzed by isolating
RNA from the donor heart and performing an RNase pro-
tection analysis. Those cytokines with detectable levels of
RNA are presented in Fig. 4, and all the cytokines tested
are listed in Table I. Increases in the type 1 cytokine IFN-g
as well as IL-15, IL-6, and IL-10 were observed in all
grafted hearts (Fig. 4). H2-DMa2/2 donor grafts from two
time points were studied: day 7 approximates the time
wild-type grafts are typically rejected, and day 20 represents
the time when H2-DMa2/2 grafts are rejected. However,
there were no differences in the level of RNA expression
between the different donor groups. There were also in-
creases in the tissue of toxic cytokines TNF-a and lympho-
toxin b, but again their levels did not appear to differ be-
tween donor groups or to correlate with the rate of
rejection. This is not entirely surprising, as enhanced graft
survival may not be associated with cytokine expression, al-
though an association between rejection episodes and Th1
cytokine expression is common (41, 42). Based on the re-
sults presented here, the enhanced survival of H2-DMa2/2
grafts is not due to a deviation of the immune response to a
different cytokine profile.
CTL Production Is Reduced in Recipients of H2-DMa2/2
Grafts. The H2-DMa defect only affects peptide loading
on class II. Class I peptide diversity is normal in these mice.
To determine if recipients of H2-DMa2/2 hearts produce
normal cytotoxic T cell activity, the presence of cytotoxic
T cells in the recipients of H2-DMa2/2 cardiac grafts was
evaluated by CTL assay. In this case, recipients of H2-
DMa2/2 hearts are less effective than recipients of B6
hearts at lysing labeled H2b targets; however, CTL activity
is clearly detectable (Fig. 5). Activation of alloreactive CTLs
can occur through direct recognition of allo–class I com-
plexes by recipient CTLs, and this class I–directed response
may be largely responsible for the rejection of H2-DMa2/2
and I-Ab
b2/2 grafts. This reduced, albeit detectable, CTL
Figure 4. Graft recipients express both
Th1 and Th2 cytokine RNA. Donor hearts
were recovered from recipient animals 7 d
after transplantation or at the time of graft
failure. Total RNA was isolated and ana-
lyzed by RNase protection analysis for the
presence and level of various cytokine tran-
scripts. No significant difference in the level
of any cytokine was observed between
groups. The cytokine profile displayed by
each recipient group was identical. Data are
means 6 SD of RNA samples from the
indicated number of animals. MIF, macro-
phage migration inhibitory factor.
Table I. Cytokine RNA Expression of Donor Grafts
Donor
Cytokine B6 H2-DMa2/2 I-Ab2/2
IFN-g1 1 1
IL-15 1/21 /21 /2
IL-6 1/21 /21 /2
IL-10 1/21 /21 /2
MIF 111 111 111
LTb 1 11 1
TGF-b1 1 1 1 1 1
TNF-a1 1 1
TNF-b1 /21 /21 /2
IL-2 22 2
IL-4 22 2
IL-5 22 2
IL-9 22 2
IL-13 22 2
IFN-b2 2 2
Cytokine RNA levels were determined by RNase protection analysis of
donor tissue harvested 7 d after graft or at the time of rejection. Both
type 1 and type 2 cytokines were elevated to an equal extent in each
recipient group (shown in Fig. 4). MIF, macrophage migration
inhibitory factor; LTb, lymphotoxin b.36 Peptide Plays a Crucial Role in Allograft Recognition
response parallels the delayed but present allograft rejection
and may reflect a decrease in CD41 T cell help.
H2-DMa2/2 Grafts have Fewer Infiltrating Leukocytes.
Decreased proliferative and CTL responses may reflect a
reduction in the number of cells infiltrating the graft. Im-
munohistochemistry of donor cardiac tissue harvested 7 d
after grafting identified a decrease in the number of infil-
trating CD41 T cells, CD81 T cells, and Mac-11 cells in
H2-DMa2/2 grafts compared with wild-type B6 grafts
(Fig. 5 C). In general, H2-DMa2/2 grafts had a small
number of CD41 T cells and CD81 T cells within the myo-
cardium, and only slightly more cells within the epicar-
dium. However, a substantial number of Mac-11 cells are
present throughout H2-DMa2/2 grafts. In contrast, sec-
tions of wild-type B6 grafts stained for CD41, CD81, and
Mac-11 cells more uniformly throughout the section. The
level of tissue destruction and the degree of staining for
CD41 and CD81 cells was much greater in wild-type B6
grafts than in H2-DMa2/2 grafts. Mac-11 cells were also
increased in wild-type B6 grafts. Consistent with a reduced
CTL response, there is a clear decrease in the number of
CD81 T cells infiltrating H2-DMa2/2 grafts. However, re-
cipients of H2-DMa2/2 grafts still develop significant CTL
activity against the graft, which likely contributes to even-
tual rejection.
Recipients of H2-DMa2/2 Grafts Generate Class I–specific
Alloantibodies. Recipients of H2-DMa2/2 grafts gener-
ated CTL activity against class I MHC. To determine if al-
loantibodies against class I MHC are also generated, the se-
rum from graft recipients was assessed for alloreactivity.
Alloantibody levels were quantitated by FACS® analysis (as
described in the Materials and Methods). Recipient serum
did not stain B cells from CBY mice (data not shown) or B
cells from mice lacking expression of both MHC class I and
class II (b2m2/2 3 I-Ab
b2/2; Fig. 6 C). This result indi-
cates that the main target of recipient alloantibodies is do-
nor MHC. Splenic B cells from I-Ab
b2/2 mice, which lack
surface expression of MHC class II, were used to detect
alloantibodies directed against MHC class I. Comparable lev-
els of class I–directed alloantibodies were detected in H2-
DMa2/2, I-Ab
b2/2, and B6 controls. When day 7 time-
matched samples were compared, each recipient group had
similar levels of alloantibodies (Fig. 6 A). IgM alloantibod-
ies were a substantially higher proportion of 7-d serum al-
loreactivity than of H2-DMa2/2 and I-Ab
b2/2 samples
collected at later time points, after isotype switching had
occurred (data not shown). Even higher levels of alloanti-
bodies were detected by 20 d, the point at which H2-
DMa2/2 and I-Ab
b2/2 grafts were rejected (Fig. 6 B). This
suggests that substantial seroreactivity against class I MHC
Figure 5. Recipients of H2-DMa2/2
cardiac grafts have reduced CTL activity
compared with recipients of B6 grafts. Sple-
nocytes from recipients of H2-DMa2/2 or
B6 grafts were harvested 7 d after transplant.
Isolated splenocytes were restimulated with
irradiated spleen cells from the same donor
strain used for the original graft. After 7 d in
culture, the restimulated recipient cells were
harvested and assayed for the ability to lyse
labeled targets. (A) CTLs from recipients of
H2-DMa2/2 ( h) or B6 (j) hearts effi-
ciently lysed allogeneic H2b targets, but (B)
did not lyse syngeneic H2d control targets.
Data are means 6 SD of at least three ani-
mals. (C) Consistent with the reduced CTL
response, immunohistochemistry of 7-d
grafts reveals a clear decrease in the number
of infiltrating CD81 T cells, as well as de-
creases in the number of CD41 and Mac-11
cells infiltrating H2-DMa2/2 grafts.37 Felix et al.
molecules is being produced in these recipients, and likely
contributes to their rejection.
Reduction of Class I Expression Further Enhances H2-
DMa2/2 Cardiac Graft Survival. The data presented thus
far suggest that rejection of H2-DMa2/2 grafts may be di-
rected against class I differences between donor and recipi-
ent animals. To further explore this possibility, H2-DMa2/2
mice were bred with b2m2/2 mice to generate donor ani-
mals deficient for class I expression, but which expressed
CLIP–I-Ab (H2-DMa2/2 3 b2m2/2). Grafts from donor
animals deficient only for b2m were rejected similarly to
wild-type B6 controls, with median survival 11 vs. 9 d, re-
spectively (Fig. 7). In contrast, donor grafts from H2-
DMa2/2 3 b2m2/2 DKO animals survived significantly
longer than control grafts and even longer than H2-DMa2/2
grafts, with a median survival of .70 d. All the DKO
grafts survived .40 d. Decreasing class I expression alone
did not alter graft survival, but in combination with the re-
moval of H-2DMa2/2  greatly enhanced graft survival.
Therefore, the antigraft response seen in H2-DMa2/2
mice was mainly directed against class I and not CLIP–I-Ab.
Discussion
Previous work established that direct recognition of allo-
MHC may occur through peptide-specific, peptide-depen-
dent, and/or peptide-independent mechanisms. One group
has even shown that peptide-independent CD81 T cell
lines reject skin grafts (23). However, it has not been possi-
ble to determine the relative contribution of each of these
responses to the rejection of a primary graft. Here, we
demonstrate the importance of peptide, not just allogeneic
MHC, in the rejection of vascularized cardiac grafts. Our
results are also supported by a recent report that failed to
detect the generation of any allo-MHC–CLIP–specific T
cells in mice primed with H2-DMa2/2 spleen cells (43).
Based on our results, peptide-independent allorecogni-
tion of class II is unlikely to contribute to the acute rejec-
tion of H2-DMa2/2 grafts. However, it is more difficult to
determine the relative contribution of peptide-specific ver-
sus peptide-dependent responses. Here, the distinction is
based on the extent of peptide specificity. Even alloreactive
T cell clones that initially seemed to support the peptide-
specific model have been shown to cross-react with a re-
lated set of degenerate peptides (13, 15–20). Of course,
TCR cross-reactivity is not unique to allorecognition (44–
49). One estimation has each T cell capable of responding
to 3 3 105 different peptides (50).
One school of thought is that peptide-dependent re-
sponses are directed toward peptide-induced conforma-
tional changes in MHC, with little or no actual interaction
between the TCR and peptide. Because distinct peptides
induce different conformational changes, each peptide will
stimulate distinct sets of peptide-dependent T cells. This
Figure 6. Recipients of H2-DMa2/2
grafts are efficient producers of alloantibod-
ies. The presence and level of serum alloan-
tibodies was determined by FACS®. (A) All
three recipient groups produce nearly equal
levels of alloantibodies directed against allo-
geneic class I 7 d after transplant. (B) Serum
collected at the time of rejection from re-
cipients of I-Ab
b2/2 or H2-DMa2/2 grafts,
z20 d, have an elevated level of class I–spe-
cific alloantibodies. (C) Recipient sera did
not stain B cells from mice lacking MHC
expression (b2m2/2 3 I-Ab
b2/2). In B and
C, data are means 6 SD of serum samples
from at least three animals.
Figure 7. Rejection of cardiac grafts from mice lacking both b2m and
H2-DMa (b2m2/2 3 H2-DMa2/2, DKO). Cardiac grafts from the in-
dicated donors (H2b) were grafted into the abdomen of CBY (H2d) recip-
ient mice. Graft survival was monitored by palpation of the abdomen.
Each point represents an individual recipient, and the line in each group
represents the median survival. Syngeneic grafts from CBY mice were not
rejected (data not shown). The median survival of cardiac grafts from
b2m2/2 controls was 11 d (n 5 7), and from DKO donors was .70 d
(n 5 6, P 5 0.0027). Statistical significance was determined using the
Mann-Whitney U test compared with b2m2/2 control donors.38 Peptide Plays a Crucial Role in Allograft Recognition
paper clearly proves that one specific peptide, CLIP, is in-
sufficient to globally activate peptide-dependent T cell re-
sponses. Peptide-dependent recognition does not occur in
recipients of H2-DMa2/2 grafts at a level strong enough to
mediate rapid rejection when only CLIP–I-Ab is provided.
The most straightforward explanation is that the enhanced
survival of the H2-DMa2/2 grafts is primarily due to the
inhibition of the peptide-specific response.
Direct recognition of allo-MHC by peptide-specific
and/or peptide-dependent recipient T cells provides a ma-
jor contribution to the rejection of vascularized heart grafts.
This interaction is dependent upon a proper structure of
the class II molecule. Because CLIP–I-Ab molecules from
H2-DMa2/2 mice are unstable in SDS and are recognized
by some, but not all, class II–specific antibodies, it is possi-
ble that the CLIP– I-Ab complex has an unusual structure
that makes it unsuitable as a model for allorecognition. Al-
though the structure of mouse CLIP–I-Ab has not been re-
ported, the structure of human CLIP–DR3 is known and
has been shown to be almost identical to the structure of
the influenza virus hemagglutinin peptide (306–318)–DR1
complex (51). It is unlikely that the binding of CLIP to
mouse class II is fundamentally different than the binding of
CLIP to human DR3. Therefore, the CLIP–I-Ab complex
should be reflective of the structure of other peptide–
mouse class II complexes. Although SDS instability does
suggest a low-affinity interaction between class II and pep-
tide, it does not indicate a structural abnormality. In fact,
SDS-unstable complexes have been shown to be capable of
inducing T cell responses in other systems (52).
It is also likely that some of the MHC molecules from
the H2 DMa2/2 animals are complexed with peptides
other than CLIP. Although the I-Ab haplotype is the most
dependent upon H2-DM for removal of CLIP, some
mouse haplotypes (e.g., I-Ak, I-Ad) can exchange peptide
in the absence of H2-DM (34–37). Although peptide load-
ing experiments showed significant impairment of class II
peptide exchange in the H2-DMa2/2 animals (25, 26, 43),
it is clear that not all class II molecules are bound to CLIP
(38, 53). This suggests that either the level of expression of
non-CLIP peptides is too low to induce a response, that
the non-CLIP peptides are nonactivating, or that the
CLIP–MHC complex is acting similarly to an altered pep-
tide ligand, not only failing to induce a response but actu-
ally inhibiting responses directed toward other peptide–
MHC complexes expressed on the same cell. It has been
shown that an abundance of an altered peptide ligand on a
cell can reduce or remove positive responses to activating
peptides present on the same cell (54).
Allogeneic MHC has been suggested to be the major
mediator of graft rejection, either through the direct inter-
action and stimulation of alloreactive T cells, or indirectly
as a source of allogeneic peptides that are acquired and pre-
sented by recipient APCs. I-Ab
b2/2 grafts, which lack
MHC class II expression, can neither stimulate alloreactive
T cells directly nor provide MHC class II peptides to stim-
ulate alloreactive T cells indirectly. On the other hand,
H2-DMa2/2 grafts do not appear to interact directly with
alloreactive T cells, but could provide MHC class II pep-
tides to stimulate alloreactive T cells indirectly. When the
survival of I-Ab
b2/2 and H2-DMa2/2 grafts is compared, a
complete absence of class II expression is no more effective
at prolonging graft survival than removing peptide diver-
sity. Therefore, indirectly presented MHC class II–derived
peptides are not primarily responsible for the accelerated
rejection of B6 grafts by CBY hosts.
The absence of class II does not prolong the survival of
all grafts. For example, class I–deficient but not class II–defi-
cient islet grafts are accepted indefinitely (55, 56), whereas
skin grafts are rapidly rejected regardless of MHC expres-
sion (57, 58). Also, the importance of minor antigens in
some instances of graft rejection cannot be ignored. Con-
sider that certain strain combinations acutely reject cardiac
grafts, even though they are matched at both MHC loci
(59–61). Nevertheless, the importance of the MHC in graft
rejection is indisputable, and is viewed as a potential point
of therapeutic intervention.
The bulk of our evidence strongly favors the interpreta-
tion that peptide plays a crucial role in the recognition and
rejection of vascularized cardiac grafts. Direct recognition
by peptide-specific and/or peptide-dependent T cells is the
key mediator of antigraft responses. However, indirect rec-
ognition of donor peptides may, in some cases, generate an
antigraft response of equal intensity. The data presented
here not only validate targeting donor class II expression as
a means of reducing graft rejection, but allow this approach
to be taken one step further. Dictating which peptide(s)
donor class II molecules can express may enhance graft sur-
vival more effectively than eliminating donor class II ex-
pression.
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